Cargando…

Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy

Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaszczyk, Izabela, Foumani, Nazli Poorsafar, Ljungberg, Christina, Wiberg, Mikael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663525/
https://www.ncbi.nlm.nih.gov/pubmed/26561833
http://dx.doi.org/10.3390/toxins7114645
_version_ 1782403314725421056
author Blaszczyk, Izabela
Foumani, Nazli Poorsafar
Ljungberg, Christina
Wiberg, Mikael
author_facet Blaszczyk, Izabela
Foumani, Nazli Poorsafar
Ljungberg, Christina
Wiberg, Mikael
author_sort Blaszczyk, Izabela
collection PubMed
description Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of the treatment. We decided to use an active surveillance of treatment-induced harm using a questionnaire we created. We studied the incidence of reported AEs and side effects in patients with CP treated with BoNT-A. We investigated the relationship between the incidence of AEs or side effects and gender, age, weight, total dose, dose per body weight, Gross Motor Function Classification System (GMFCS) and number of treated body parts. Seventy-four patients with CP participated in our study. In 54 (51%) of 105 BoNT-A treatments performed in 45 (61%) patients, there were 95 AEs and side effects reported, out of which 50 were generalized and/or focal distant. Severe AEs occurred in three patients (4%), and their BoNT-A treatment was discontinued. Consecutive collection of the AE and side-effect incidence using our questionnaire can increase the safety of BoNT-A treatment in patients with CP.
format Online
Article
Text
id pubmed-4663525
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46635252015-12-10 Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy Blaszczyk, Izabela Foumani, Nazli Poorsafar Ljungberg, Christina Wiberg, Mikael Toxins (Basel) Article Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of the treatment. We decided to use an active surveillance of treatment-induced harm using a questionnaire we created. We studied the incidence of reported AEs and side effects in patients with CP treated with BoNT-A. We investigated the relationship between the incidence of AEs or side effects and gender, age, weight, total dose, dose per body weight, Gross Motor Function Classification System (GMFCS) and number of treated body parts. Seventy-four patients with CP participated in our study. In 54 (51%) of 105 BoNT-A treatments performed in 45 (61%) patients, there were 95 AEs and side effects reported, out of which 50 were generalized and/or focal distant. Severe AEs occurred in three patients (4%), and their BoNT-A treatment was discontinued. Consecutive collection of the AE and side-effect incidence using our questionnaire can increase the safety of BoNT-A treatment in patients with CP. MDPI 2015-11-06 /pmc/articles/PMC4663525/ /pubmed/26561833 http://dx.doi.org/10.3390/toxins7114645 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Blaszczyk, Izabela
Foumani, Nazli Poorsafar
Ljungberg, Christina
Wiberg, Mikael
Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
title Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
title_full Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
title_fullStr Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
title_full_unstemmed Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
title_short Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
title_sort questionnaire about the adverse events and side effects following botulinum toxin a treatment in patients with cerebral palsy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663525/
https://www.ncbi.nlm.nih.gov/pubmed/26561833
http://dx.doi.org/10.3390/toxins7114645
work_keys_str_mv AT blaszczykizabela questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy
AT foumaninazlipoorsafar questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy
AT ljungbergchristina questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy
AT wibergmikael questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy